Pancreatic Cancer Research

ResearcherNational Taiwan UniversityActive in the last 2 years

Shih‐Hung Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0391-752X; OpenAlex author ID A5108056600. Sources: ClinicalTrials.gov.

Their work

Papers
32 (first author 4, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 3 papers · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 5 papers · 2022: 8 papers, 1 trial · 2023: 1 paper · 2024: 3 papers · 2025: none · 2026: 2 papers

Papers 32

  1. Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort. Co-author DOI 10.1016/j.jfma.2026.04.039↗
  2. Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort… Co-author DOI 10.1016/j.jfma.2026.05.008↗
  3. Adding-on nivolumab to chemotherapy-stabilized patients is associated with improved survival in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00262-024-03821-3↗
  4. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation. Co-author DOI 10.1016/j.bj.2023.100696↗
  5. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer. First author DOI 10.1016/j.pan.2024.03.014↗
  6. Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers15041008↗
  7. Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovo… First author DOI 10.1002/jhbp.1128↗
  8. A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative On… Co-author DOI 10.1038/s41416-021-01649-7↗
  9. Maintenance therapy of low-dose nivolumab, S-1, and leucovorin in metastatic pancreatic adenocarcinoma with a germline mutation of MSH6: A case report. Last author DOI 10.3389/fimmu.2022.1077840↗
  10. Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fimmu.2022.870406↗
  11. Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. Co-author DOI 10.3389/fonc.2022.800842↗
  12. The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan. Co-author PMID 35530292↗
  13. Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma rec… Co-author PMID 36225629↗
  14. The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic duc… Co-author PMID 36504882↗
  15. C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes cell invasiveness through integrin αv. Co-author DOI 10.1038/s41388-020-01594-4↗
  16. Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2021.1973710↗
  17. Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study. Co-author DOI 10.1177/17588359211058255↗
  18. Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating N… First author DOI 10.1186/s12935-021-02143-z↗
  19. Metabolic Alterations in Pancreatic Cancer Detected by In Vivo 1H-MR Spectroscopy: Correlation with Normal Pancreas, PET Metabolic Activity, Clinical Stages, a… Co-author DOI 10.3390/diagnostics11091541↗
  20. Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients. Co-author DOI 10.1016/j.jfma.2019.01.015↗
  21. S-1-Associated Hypertriglyceridemia in a Patient With Pancreatic Adenocarcinoma. Last author DOI 10.1200/jop.19.00204↗
  22. Postoperative Imaging and Tumor Marker Surveillance in Resected Pancreatic Cancer. Co-author DOI 10.3390/jcm8081115↗
  23. Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer. Co-author DOI 10.1007/s00259-018-3960-0↗
  24. A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.21873/anticanres.12790↗
  25. Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine… Co-author DOI 10.1371/journal.pone.0180628↗
  26. Pancreatic cancer screening in different risk individuals with family history of pancreatic cancer-a prospective cohort study in Taiwan. Co-author PMID 28337383↗
  27. Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer. Co-author DOI 10.1111/jgh.13395↗
  28. Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1373/clinchem.2015.248260↗
  29. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. Co-author DOI 10.3748/wjg.v22.i32.7275↗
  30. Sequential gemcitabine and platinum versus first-line combination of gemcitabine and platinum for advanced pancreatic cancer treatment: a retrospective study. First author DOI 10.1007/s10147-013-0622-x↗
  31. Nuclear expression of glioma-associated oncogene homolog 1 and nuclear factor-κB is associated with a poor prognosis of pancreatic cancer. Co-author DOI 10.1159/000353452↗
  32. Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials. Co-author DOI 10.1159/000330817↗

Trials 1

  1. Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma Principal investigator NCT05363007↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Li‐Yuan Bai · 13 shared papers, 2021–2026 · strength 2.06
  2. Chung‐Pin Li · 12 shared papers, 2021–2026 · strength 1.89
  3. Yung‐Yeh Su · 11 shared papers, 2021–2026 · strength 1.77
  4. Wen‐Chi Chou · 11 shared papers, 2021–2026 · strength 1.75
  5. Tai‐Jan Chiu · 11 shared papers, 2021–2026 · strength 1.75
  6. Yu‐Wen Tien · 15 shared papers, 2011–2024 · strength 1.56
  7. Sung‐Hsin Kuo · 13 shared papers, 2011–2024 · strength 1.44
  8. Yan‐Shen Shan · 10 shared papers, 2021–2024 · strength 1.42
  9. Nai‐Jung Chiang · 10 shared papers, 2021–2024 · strength 1.39
  10. Yen‐Yang Chen · 9 shared papers, 2021–2024 · strength 1.25
  11. Jen‐Shi Chen · 9 shared papers, 2021–2024 · strength 1.25
  12. Bang‐Bin Chen · 8 shared papers, 2017–2024 · strength 1.16
  13. Li‐Tzong Chen · 8 shared papers, 2021–2024 · strength 1.07
  14. Cheng‐Ming Peng · 8 shared papers, 2021–2024 · strength 1.06
  15. Ann‐Lii Cheng · 10 shared papers, 2011–2024 · strength 0.99
  16. Kun‐Huei Yeh · 7 shared papers, 2016–2024 · strength 0.84
  17. Ting‐Chun Kuo · 6 shared papers, 2016–2022 · strength 0.67
  18. Jhe‐Cyuan Guo · 6 shared papers, 2014–2020 · strength 0.54
  19. Hsiu-Tzu Wang · 2 shared papers, 2026 · strength 0.50
  20. I‐Wei Ho · 2 shared papers, 2026 · strength 0.50
  21. Yu‐Ting Chang · 4 shared papers, 2016–2021 · strength 0.34
  22. Ming‐Chu Chang · 4 shared papers, 2016–2021 · strength 0.34
  23. Tiffany Ting‐Fang Shih · 2 shared papers, 2018–2021 · strength 0.22
  24. Mei‐Fang Cheng · 2 shared papers, 2018–2021 · strength 0.22
  25. Shang‐Hsuan Peng · 1 shared paper, 2022 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.